AbbVie’s Neuroscience Business Looks Set to Remain a Major Growth Driver in 2026
AbbVie’s Neuroscience Business Looks Set to Remain a Major Growth Driver in 2026
AbbVie appears well positioned to keep its neuroscience segment as an important engine of revenue growth in 2026. After posting strong full-year 2025 results, the company entered 2026 with momentum across several neuroscience brands, including Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, and the newer Parkinson’s disease treatment Vyalev. In its full-year 2025 results announced on February 4, 2026, AbbVie said neuroscience revenue reached $10.767 billion, up 19.6% year over year, and the company indicated that the franchise could climb to about $12.5 billion in 2026, implying another year of solid expansion.
Why Neuroscience Matters More Than Ever for AbbVie
AbbVie has been reshaping its business since the loss of U.S. exclusivity for Humira, once one of the biggest drugs in the industry. While immunology products such as Skyrizi and Rinvoq now lead the company’s overall growth story, neuroscience has become one of AbbVie’s most dependable supporting pillars. That matters because AbbVie is no longer relying on a single blockbuster medicine to carry its top line. Instead, it is building a more balanced portfolio, and neuroscience is now a central part of that effort. AbbVie’s 2025 results show this clearly: neuroscience was one of the company’s fastest-growing major segments, helping offset continued pressure from older products in other categories.
For investors and industry watchers, the key question is not whether neuroscience helped in 2025. It clearly did. The real question is whether this business can continue lifting AbbVie’s revenue in 2026. Based on the company’s guidance, recent product trends, and expansion opportunities in migraine and Parkinson’s disease, the answer appears to be yes, though not without some risks.
AbbVie’s 2025 Neuroscience Performance Set a Strong Base for 2026
Full-Year Growth Was Broad-Based
AbbVie’s neuroscience division did not rely on just one drug in 2025. According to the company’s full-year results, the segment generated $10.767 billion in revenue. Within that total, Vraylar contributed $3.621 billion, Botox Therapeutic added $3.769 billion, and the combined revenue from Ubrelvy and Qulipta reached $2.307 billion. This mix is important because it shows AbbVie has multiple neuroscience products contributing meaningful revenue rather than a narrow, single-product growth story.
Fourth-Quarter Momentum Stayed Strong
Momentum continued into the end of 2025. In the fourth quarter alone, AbbVie reported neuroscience revenue of $2.961 billion, up 17.9% on a reported basis. During that quarter, Vraylar generated $1.022 billion, Botox Therapeutic brought in $990 million, Ubrelvy posted $339 million, and Qulipta added $288 million. Those numbers suggest the business was not slowing as 2025 ended. In fact, the segment entered 2026 with clear operating momentum.
Growth Was Visible Earlier in the Year Too
The fourth quarter was not an isolated spike. In the third quarter of 2025, neuroscience revenue rose to $2.841 billion, up 20.2%. At that time, Ubrelvy was up 31.5% and Qulipta was up 64.1%, showing that AbbVie’s migraine portfolio was expanding quickly well before year-end. Botox Therapeutic also delivered double-digit growth, while Vraylar remained a high-volume contributor. This steady progression across quarters supports the view that 2026 growth is being built on a durable trend rather than a one-off event.
The Main Products Driving the 2026 Outlook
Vraylar Remains a Reliable Anchor
Vraylar continues to be one of AbbVie’s biggest neuroscience brands. The drug crossed the billion-dollar mark in fourth-quarter 2025 sales alone, and its full-year 2025 revenue exceeded $3.6 billion. Even though its growth rate is lower than some newer brands, Vraylar still plays a critical role because of its large scale and stable demand. A product at this size does not need explosive growth to remain valuable. Even moderate expansion from such a large base can make a meaningful difference to AbbVie’s top line.
For 2026, Vraylar is expected to remain one of the segment’s foundation products. It may not be the fastest mover in percentage terms, but it gives AbbVie a stable earnings base within neuroscience. That stability matters when the company is also trying to scale newer medicines in migraine and Parkinson’s disease.
Botox Therapeutic Keeps Delivering
Botox is often associated with aesthetics, but its therapeutic use is a major neuroscience asset for AbbVie. Therapeutic Botox generated $3.769 billion in 2025 and nearly $1 billion in the fourth quarter alone. In the third and fourth quarters of 2025, the brand posted double-digit gains, confirming that the therapeutic business remains healthy even as the aesthetics market has faced softer conditions in some periods.
That distinction is important. While Botox Cosmetic is reported under aesthetics, Botox Therapeutic sits inside neuroscience and supports the segment with a sizable and relatively established revenue stream. Public reporting tied to the 2026 outlook suggests therapeutic Botox is expected to grow at a high-single-digit pace this year. That is not hypergrowth, but from a very large base it can still add several hundred million dollars in incremental revenue.
Ubrelvy and Qulipta Offer Faster Growth Potential
If Vraylar and Botox Therapeutic provide scale and stability, Ubrelvy and Qulipta offer growth acceleration. These migraine medicines have become increasingly important to AbbVie’s neuroscience strategy. In the third quarter of 2025, Ubrelvy rose 31.5% and Qulipta rose 64.1%. In the fourth quarter, Ubrelvy still grew 12.0% while Qulipta increased 42.6%. Combined full-year revenue from Ubrelvy and Qulipta surpassed $2.3 billion.
Qulipta may be especially important in 2026. In June 2025, AbbVie announced positive Phase 3 head-to-head results showing Qulipta outperformed topiramate on tolerability and met all secondary endpoints in migraine prevention. Reuters reported that 12.1% of patients on Qulipta discontinued treatment because of side effects, compared with 29.6% for topiramate, while 64.1% of Qulipta-treated patients achieved at least a 50% reduction in monthly migraine days versus 39.3% for topiramate. Those results could strengthen physician confidence and improve the drug’s commercial profile.
Ubrelvy also adds strategic value because it targets acute migraine treatment, while Qulipta focuses on prevention. Together, they give AbbVie a broader migraine franchise instead of a single-product presence. That kind of franchise approach can improve prescriber relationships, payer discussions, and brand stickiness over time. It also reduces the risk that one product alone must carry all of the category’s growth.
Vyalev Could Be the Wild Card Upside Story
A newer growth lever is Vyalev, AbbVie’s treatment for adults with advanced Parkinson’s disease. The U.S. FDA approved Vyalev in October 2024, and AbbVie said at the time that the therapy had already been approved in 35 countries under the name Produodopa, with more than 4,200 patients worldwide having started treatment. The therapy is designed as a 24-hour continuous subcutaneous infusion and addresses motor fluctuations in advanced Parkinson’s disease.
By the third quarter of 2025, Vyalev had already begun contributing commercially, with third-quarter sales of $138 million cited in secondary market reporting based on AbbVie’s results. Public summaries of AbbVie’s 2026 expectations suggest management believes Vyalev can become a blockbuster product, meaning annual sales above $1 billion. That would make it one of the most important new contributors to the neuroscience segment in 2026 if uptake continues as expected.
Why 2026 Revenue Growth in Neuroscience Looks Achievable
Management’s Target Implies Another Strong Year
Public reporting tied to AbbVie’s latest outlook indicates the company expects neuroscience franchise revenue of about $12.5 billion in 2026. Compared with 2025 revenue of $10.767 billion, that suggests roughly 16% year-over-year growth. For a business already above $10 billion in annual revenue, that is a notable target. It implies AbbVie believes demand remains strong across its core brands and that newer products can add enough incremental sales to keep the segment growing at a pace well above typical mature pharma averages.
AbbVie Has More Than One Growth Driver
One reason the target looks realistic is diversification inside the neuroscience portfolio itself. Vraylar provides scale. Botox Therapeutic provides consistency. Ubrelvy and Qulipta provide faster category growth in migraine. Vyalev adds a fresh launch opportunity in Parkinson’s disease. This mix makes the segment less fragile than one built around a single flagship product. If one brand slows, another may still outperform.
Neuroscience Fits AbbVie’s Post-Humira Strategy
AbbVie’s broader strategy has been to replace Humira dependence with multiple growth engines. Reuters reported in early 2025 that AbbVie had been investing heavily in neuroscience, oncology, and Alzheimer’s-related assets through acquisitions and pipeline expansion. That strategy gained even more importance after Humira faced biosimilar competition. Neuroscience is therefore not just a side business for AbbVie. It is one of the areas management has chosen to support long-term portfolio diversification.
Risks That Could Limit the Segment’s Help to the Top Line
Large Products Inevitably Face Tougher Comparisons
The biggest challenge for AbbVie’s neuroscience business in 2026 may be that some brands are already large and well established. As products mature, it becomes harder to maintain rapid percentage growth. Vraylar and Botox Therapeutic can still expand, but their year-over-year gains may moderate simply because the revenue base is already so high. That means AbbVie will likely need newer drivers such as Qulipta and Vyalev to do more of the heavy lifting if it wants to reach the full $12.5 billion target.
Competition in Migraine Remains Real
Migraine is an attractive market, but it is competitive. Qulipta and Ubrelvy must continue fighting for share in a field that includes other branded options and generic therapies. AbbVie’s positive head-to-head data for Qulipta may help, especially on tolerability, but translating clinical wins into broad payer access and prescribing gains is never automatic. The migraine market can reward strong data, yet commercial execution still matters.
Launch Execution for Vyalev Must Stay Strong
Vyalev may offer upside, but it also carries launch risk. Advanced Parkinson’s disease treatment can involve training, device support, reimbursement complexity, and careful patient selection. That means even a promising therapy may ramp more gradually than expected if real-world adoption encounters friction. AbbVie appears optimistic, but blockbuster status in 2026 will still depend on smooth commercial execution.
Broader Portfolio Pressures Still Matter
Even if neuroscience performs well, AbbVie’s total company results are shaped by other divisions too. Reuters noted that while AbbVie’s 2026 profit outlook topped expectations, investors remained focused on the composition of growth, particularly the pace of newer medicines versus pressure from older assets and policy-related issues such as Medicare price negotiations affecting certain products. So neuroscience can help the top line significantly, but it does not operate in a vacuum.
How Neuroscience Fits into AbbVie’s Bigger 2026 Revenue Picture
AbbVie’s company-wide 2026 guidance called for adjusted diluted earnings per share of $14.37 to $14.57. At the same time, the company said 2025 total net revenue rose to $61.160 billion, with fourth-quarter revenue reaching $16.618 billion. Those figures show AbbVie is operating from a large and growing base. Within that context, a neuroscience business expected to approach or exceed $12 billion becomes highly meaningful. It is no longer just a secondary support unit. It is a major contributor to growth and scale.
This matters especially because AbbVie’s immunology franchise, while still dominant, cannot be the sole source of expansion forever. A stronger neuroscience segment gives the company another sizable leg of growth. The more balanced AbbVie becomes across immunology, neuroscience, oncology, and aesthetics, the more resilient its revenue profile may look to the market. That balance is one reason neuroscience’s continued progress in 2026 is so important beyond the segment itself.
Market Takeaway: Will Neuroscience Continue to Aid the Top Line in 2026?
All signs point to yes. AbbVie finished 2025 with strong neuroscience momentum, broad-based product growth, and a management outlook that calls for another year of double-digit expansion. The segment has scale, diversity, and several catalysts. Vraylar remains a dependable anchor. Botox Therapeutic continues to generate steady gains from a large base. Ubrelvy and Qulipta give AbbVie a growing migraine platform. Vyalev offers a meaningful launch opportunity in Parkinson’s disease. Together, these assets support the view that neuroscience can continue helping AbbVie’s revenue line in 2026.
The segment may not be the single biggest piece of AbbVie’s growth puzzle, because immunology still carries enormous weight. But neuroscience is increasingly one of the company’s most valuable growth engines. If AbbVie executes well in migraine and Parkinson’s disease while maintaining stability in Vraylar and Botox Therapeutic, the neuroscience portfolio should remain a powerful support for the company’s top-line expansion this year. For now, the evidence suggests this business is not just aiding revenue growth. It is becoming one of the pillars that helps define AbbVie’s post-Humira era.
Additional Context for Readers and Investors
What Makes This Segment Different from AbbVie’s Other Units?
Neuroscience stands out because it combines mature revenue sources with newer launch assets. In immunology, the conversation often revolves around massive blockbusters such as Skyrizi and Rinvoq. In aesthetics, performance can be affected by consumer spending patterns. In oncology, AbbVie is still strengthening its portfolio with deals and pipeline additions. Neuroscience, by contrast, already has multiple commercial products across psychiatric disorders, migraine, therapeutic neurology, and Parkinson’s disease. That gives the segment a rare balance of present revenue and future upside.
Why the 2026 Forecast Is Closely Watched
The 2026 forecast for neuroscience is closely watched because it offers a test of AbbVie’s ability to create durable growth beyond its legacy blockbuster era. If the segment reaches around $12.5 billion, it would prove that AbbVie is successfully building a broader platform rather than simply replacing one product with another. It would also reinforce confidence that AbbVie can keep expanding even as the pharmaceutical industry faces pricing pressure, competition, and investor scrutiny over pipeline execution.
A Useful External Source for Company Information
Readers looking for the company’s primary financial release can review AbbVie’s official investor materials and corporate news pages, where the company published its full-year 2025 and fourth-quarter 2025 results on February 4, 2026. That primary release remains the clearest source for the segment revenue figures discussed in this rewritten report.
#AbbVie #Neuroscience #BiotechNews #HealthcareStocks #SlimScan #GrowthStocks #CANSLIM